EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report

Sara Boukansa iD, Ismail Mouhrach, Fatima El Agy iD, Sanae El Bardai, Laila Bouguenouch, Mounia Serraj, Bouchra Amara, Yassine Ouadnouni, Mohamed Smahi, Badreeddine Alami, Nawfel Mellas, Zineb Benbrahim und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0298721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Sara Boukansa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biomedical and Translational Research, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-small cell lung cancer (NSCLC) remains a significant global health concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This prospective study investigated the prevalence and clinical implications of EGFR mutations in Moroccan NSCLC patients.

Methods

A cohort of 302 NSCLC patients was analyzed for EGFR mutations using multiple techniques. Demographic, clinical, and pathological characteristics were assessed, and overall survival (OS) outcomes were compared among different EGFR mutation subtypes.

Results

EGFR mutations were present in 23.5% of patients, with common mutations (81.69%) dominating. Common mutations showed strong associations with female gender and non-smoking status, while rare mutations were associated with a positive smoking history. Patients with EGFR mutations receiving tyrosine kinase inhibitors (TKIs) had significantly improved OS compared to wild-type EGFR patients. Notably, patients with common EGFR mutations had the highest OS, while those with rare mutations had a shorter survival period, albeit not statistically significant.

Conclusion

This study highlights the relevance of EGFR mutation status in NSCLC patients, particularly in therapeutic decision-making. The association between smoking history and rare mutations suggests the need for tailored approaches. The survival advantage for patients with common EGFR mutations underscores the significance of personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationHumansFemaleMaleMiddle AgedMoroccoPrognosisAgedAdultProspective StudiesAged, 80 and over

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Laboratory of Biomedical and Translational Research, Faculty of Medicine and Pharmacy, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
  • Laboratory of Anatomic Pathology and Molecular Pathology, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
  • Unit of Medical Genetics and Oncogenetics, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
  • Department of Pneumology, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
  • Department of Thoracic Surgery, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
  • Department of Radiology, University Hospital Hassan II, Sidi Mohamed Ben Abdellah University, Fez, Morocco.

ORCID-Profile: Sara Boukansa, Fatima El Agy

Zitieren

APA

Boukansa, S., Mouhrach, I., El Agy, F., El Bardai, S., Bouguenouch, L., Serraj, M., Amara, B., Ouadnouni, Y., Smahi, M., Alami, B., Mellas, N., Benbrahim, Z., & El Fatemi, H. (2024). Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report. PLOS ONE. https://doi.org/10.1371/journal.pone.0298721

Vancouver

Boukansa S, Mouhrach I, El Agy F, El Bardai S, Bouguenouch L, Serraj M, et al. Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report. PLOS ONE. 2024. doi:10.1371/journal.pone.0298721

BibTeX
@article{Boukansa2024,
  author = {Boukansa, Sara and Mouhrach, Ismail and El Agy, Fatima and El Bardai, Sanae and Bouguenouch, Laila and Serraj, Mounia and Amara, Bouchra and Ouadnouni, Yassine and Smahi, Mohamed and Alami, Badreeddine and Mellas, Nawfel and Benbrahim, Zineb and El Fatemi, Hinde},
  title = {Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0298721}
}
Kostenlos starten →